Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Alimera Sciences (ALIM) Stock Forecast & Price Target

Alimera Sciences logo
Get the Latest News and Ratings for ALIM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alimera Sciences and its competitors.

Sign Up

ALIM Analyst Ratings Over Time

TypeCurrent Forecast
12/23/23 to 12/22/24
1 Month Ago
11/23/23 to 11/22/24
3 Months Ago
9/24/23 to 9/23/24
1 Year Ago
12/23/22 to 12/23/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
2 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$8.00$8.00$8.00$6.50
Forecasted Upside44.40% Upside44.40% Upside44.40% Upside68.39% Upside
Consensus Rating
Hold
Hold
Hold
Buy

ALIM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALIM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Alimera Sciences Stock vs. The Competition

TypeAlimera SciencesMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.81
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside44.40% Upside25,827.32% Upside14.53% Upside
News Sentiment Rating
Neutral News

See Recent ALIM News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/25/2024Alliance Global Partners
1 of 5 stars
J. Molloy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
6/25/2024Maxim Group
4 of 5 stars
N. Rahman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
6/25/2024HC Wainwright
2 of 5 stars
Y. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$6.00+8.30%
4/3/2023Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$18.00 ➝ $8.00+321.05%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 10:00 AM ET.


ALIM Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Alimera Sciences is $8.00, with a high forecast of $10.00 and a low forecast of $6.00.

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALIM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALIM, but not buy additional shares or sell existing shares.

According to analysts, Alimera Sciences's stock has a predicted upside of 44.40% based on their 12-month stock forecasts.

Analysts like Alimera Sciences less than other "medical" companies. The consensus rating for Alimera Sciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ALIM compares to other companies.


This page (NASDAQ:ALIM) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners